Influenza vaccine live (MedImmune)

The U.S. Department of Health and Human Services and NIH have announced "Generation Gold Standard," a next-generation universal vaccine platform using beta-propiolactone-inactivated whole-virus technology.

AIM ImmunoTech initiates development of Ampligen as a vaccine adjuvant for avian influenza, partnering with Amarex Clinical Research for IND application management.

AIM ImmunoTech highlights the continued development of Ampligen (rintatolimod) across multiple clinical programs targeting pancreatic cancer and Long-COVID.

Dupilumab (Dupixent) gains FDA approval as the first treatment specifically for children aged 1-11 with eosinophilic esophagitis, addressing a critical unmet need for this age group.

The FDA approved Vertex's Alyftrek for cystic fibrosis, offering improved dosing and potential market exclusivity.